Fixed Drug Eruption Caused by Etoricoxib

ABSTRACT

Etoricoxib is a COX 2 selective inhibitor it has one of the highest cox 2 selectivity and is one of the newer coxib class drug. Etoricoxib is an orally active cox 2 selective inhibitor that acts by blocking the cox 2 enzyme thereby reducing the formation of pro inflammatory prostaglandins without significantly affecting cox 1, which helps maintain GI protection and platelet function. Etoricoxib belongs to the NSAIDS class and exhibits anti-inflammatory, analgesic and antipyretic properties. A 56-year-old female patient was admitted for the management of hypertension. During her history taking she reported a highly pigmented deep bruise in her right thigh. She was diagnosed with osteoarthritis 2 years back and had been taking oral Etoricoxib 90 mg for pain management for the past 1 year. Overtime she noticed that a black discoloured bruise started appearing on her upper thigh. On examination it was confirmed that a fixed drug eruption was likely caused by prolonged Etoricoxib use. The medication was discontinued and tramadol 40 mg was prescribed for pain relief. Fusidic acid cream was applied locally to aid skin recovery. This case highlights the importance of use of NSAIDS like Etoricoxib particularly in long term therapy. Prolonged use can lead to adverse effects such as fixed drug eruptions and unexplained bruising. Regular monitoring, early identification of side effects and timely withdrawal of the offending drug are essential to prevent complications and ensure patients.

KEYWORDS

• ADRs
• Etoricoxib
• NSAIDS
• Fixed Drug Eruptions

Showing references and in-text citations exactly as published.

• DOI10.5530/ijopp.20260477Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPP.

• Article · VOLUME 19, ISSUE 3A Case Lichen Planus Pigmentosus an Uncommon Entity with Distinctive Characteristics: A Case ReportMuhammed Salah, Muhammed Shas, Nahdha K, Shariba Parveen, Anjali C S, Kameswaran R, Sirajudheen M K · pp. 389–391Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3A Challenging Case of High-Risk Pediatric AML with Novel ZNF348/SF11 Fusion and Mixed Phenotypic Features: Navigating Genomic Complexity, Resistant Infections, and MRD-Driven Therapy toward RemissionC. Dhandapani, Kavitha A · pp. 392–394Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3A Case of Dry Gangrene in an Autoimmune Patient: Diagnostic and Therapeutic ChallengesParshant Pokhriyal, Muskan Kumari, Damini Kharb, Subodh Gururani, Anuj Nautiyal · pp. 397–402Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3Ofloxacin/Ornidazole Induced Toxic Epidermal Necrolysis: Case ReportSyed Zia Inamdar, Chirasini Swapna, Pavan Kumar, Sushilkumar Londhe, Sanjeev Bentoor, Ajith Janagond, Shrinivas Raikar · pp. 403–406Case ReportSame type: Article